Investigational agents to treat hematologic malignancy in pipeline
May 4th 2020Blastic plasmacytoid dendritic neoplasm (BPDCN) is a rare but aggressive hematologic malignancy that often manifests with asymptomatic skin lesions that often appear as bruise-like lesions, plaques or nodules. With one approved drug available, researchers are studying additional investigational agents.
Consider lesion biopsy in patients with history of certain cancers
May 4th 2020While little is known about BPDCN and how to treat it, authors of a recent study suggest a low threshold for performing a skin biopsy to evaluate skin lesions in patients with hematological cancers, especially when those lesions that are quickly progressing, large or involve atypical sites.
Meta-analysis points to most effective biologics for psoriasis
April 15th 2020Brodalumab, guselkumab, ixekizumab and risankizumab stood out among 15 biologic and oral medications as having the highest short- and long-term response rates for the treatment of moderate-to-severe plaque psoriasis, according to a recent meta-analysis.